MedCrypt is expanding cybersecurity partnerships with leading diabetes technology companies to bring digital innovation to millions of people worldwide

MedCrypt’s solutions promote secure interoperability for patient-side devices to provide digital healthcare solutions for diabetes care

SAN DIEGO, Feb. 14, 2023 /PRNewswire/ — MedCrypt, Inc., the provider of proactive cybersecurity solutions for medical device manufacturers, today announced it is working with six diabetes care technology providers, including leading manufacturers of insulin pumps and continuous blood glucose meters, to enable the next-generation diabetes technology with built-in safety to market faster.

Approximately 37.3 million Americans live with diabetes, and of those an estimated 350,000 use insulin pumps daily. The Food and Drug Administration (FDA) has been tracking the potential cybersecurity risks associated with the use of insulin pumps and blood glucose meters and has determined that unauthorized users could gain access to these devices while pairing users with other system components such as smartphones. Due to the high utility of these devices, they must be reliable and trustworthy. Many diabetes devices are connected, increasingly working together and delivering life-saving dosages, meaning it’s critical they only work with authorized and authenticated parts.

“Diabetes is a constant disruption in the lives of millions of people, and digital technology brings peace and convenience so people with diabetes can take control of their own health,” said Mike Kijewski, CEO of MedCrypt. “But digital innovation also requires security innovation. The devices themselves must ‘trust’ each other by binding a unique cryptographic certificate to a device. This area of ​​digital technology couldn’t be more in line with why MedCrypt exists. We solve the unique security challenges in digital healthcare – at scale – so our customers can confidently create the clinical innovations of the future.”

READ :  Interpol Trains Crimefighters in the Metaverse

“The need for proactive cybersecurity in diabetes devices is growing; with the benefits of connected devices comes the potential to expose multiple connected devices to cyber threats,” said Naomi Schwartz, senior director of quality and safety at MedCrypt. Her background includes working at the FDA evaluating software and cybersecurity for the world’s first regulated automated insulin delivery (AID) system and developing Class II regulatory pathways for the three major components of AID systems, a game changer in helping insulin-dependent patients Diabetes. “The data shows that hospital doctors and pharmacists are thinking about safety and that they need clearer information about privacy, safety and data sharing before prescribing diabetes technology to their patients. But with that in mind, healthcare providers cannot be specialists in this technology themselves and the potential privacy issues. You need a specialist that offers security and privacy guarantees; MedCrypt empowers companies to move faster, build better, safer, more connected devices, and enables physicians to prescribe devices without worrying about the security of connectivity.”

The story goes on

“People living with diabetes are the best experts on their chronic condition. They live with these devices every day; we couldn’t possibly know more about the effects of their devices than they do,” said Shannon Lantzy, vice president of consulting at MedCrypt . “We understand the importance of interoperability. MedCrypt works with vendors to develop technologies that provide trust, transparency, interoperability, and choice.”

MedCrypt currently provides advanced security products and services to seven of the top 10 medical device manufacturers and start-ups and mid-sized companies, including the leading manufacturers of surgical robotic technology and virtual reality applications for minimally invasive surgery.

READ :  NFMLA celebrates aspiring filmmakers with stories of love and erasure

In early November 2022, MedCrypt announced a $25 million Series B funding round, followed by additional investments from Dexcom Ventures in January 2023. The company will use these funds to expand its cryptography, behavior monitoring, and vulnerability management products to various medical devices, such as glucose monitors and other diabetes devices. For more information about MedCrypt and its suite of security solutions, visit

About MedCrypt

MedCrypt helps healthcare technology companies ensure medical devices are inherently secure. We provide cybersecurity products and strategic management consulting to accelerate the time to market of medical device manufacturers’ new life-saving connected technologies.

Founded in 2016 by a team of healthcare cybersecurity experts, MedCrypt is uniquely positioned to be the security catalyst for medical device manufacturers to develop secure, FDA-cleared technologies. We continue to work with those who pave the way to safe and reliable medical technology. To date, MedCrypt has raised more than $36 million in funding with participation from Johnson & Johnson Innovations, Intuitive Ventures and Dexcom Ventures. Visit for more information.

Press contact:
Jenny Bourne


View original content to download multimedia: -for-millions-of-people-worldwide-301746428.html